Orexigen Therapeutics — Technical Presentation (January 2009)
14 slides from Orexigen Therapeutics's technical presentation, Jan 9, 2009
Slide 1: NB-302 Top-line Efficacy and Safety Results
Exhibit 99.3 Orexigen® Therapeutics, Inc. NB-302 Top-line Efficacy and Safety Results January 8, 2009 Slide 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “assuming” and similar expressions are intended to identify forward-looking statements. Thes
Slide 3: NB-302: Goals and objectives
NB-302: Goals and objectives Goal: To demonstrate comparative efficacy of Contrave ® and placebo, with a robust underlying behavioral intervention (including diet and exercise). Co-Primary endpoints: Change from baseline in percentage of total body weight loss Proportion of subjects who lose at leas
Slide 4: NB-302: Study Design
NB-302: Study Design Design: Bupropion SR 360mg / naltrexone SR 32mg (NB32) vs. placebo, with underlying behavior modification regimen in a 3:1 randomization Sample Size: 793 randomized subjects (591 NB32, 202 Placebo) Duration: 56 weeks (4 week titration, 52 week maintenance) Location: 9 US sites 2
Slide 5: NB-302: Baseline Characteristics
NB-302: Baseline Characteristics Placebo NB32 N=202 N=591 Age, mean (SD) 45.6 (11.4) 45.9 (10.4) Sex, Female, n (%) 185 (91.6%) 528 (89.3%) Race, White, n (%) 149 (73.8%) 405 (68.5%) Weight (kg), mean (SD) 101.9 (15.0) 100.2 (15.4) BMI, mean (SD) 37.0 (4.2) 36.3 (4.2) Waist Circumference (cm), mean
Slide 6: NB-302: Body Weight, Percent Change from Baseline to Endpoint
NB-302: Body Weight, Percent Change from Baseline to Endpoint p<0.001 p<0.001 ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 measurement Slide 6
Slide 7: NB-302: Body Weight, Percent Change from Baseline by Visit (Observed Case)
NB-302: Body Weight, Percent Change from Baseline by Visit (Observed Case) p-value <0.001 between NB32 and placebo at all study visits Slide 7
Slide 8: NB-302: Body Weight, Proportion of Subjects 5% Weight Loss from Baseline
NB-302: Body Weight, Proportion of Subjects 5% Weight Loss from Baseline p<0.001 p<0.001 ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 measureme
Slide 9: NB-302: Body Weight, Proportion of Subjects 10% Weight Loss from Baseline
NB-302: Body Weight, Proportion of Subjects 10% Weight Loss from Baseline p<0.001 p<0.001 * ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 measur
Slide 10: NB-302: Body Weight, Proportion of Subjects 15% Weight Loss from Baseline
NB-302: Body Weight, Proportion of Subjects 15% Weight Loss from Baseline p<0.001 p<0.001 ITT analysis set: all randomized subjects with baseline and at least one post-baseline measurement on study drug (Week 56 LOCF) Completer analysis set: all randomized subjects with baseline and Week 56 measurem
Slide 11: NB-302: Secondary Measures, Change from Baseline, ITT (LOCF)
NB-302: Secondary Measures, Change from Baseline, ITT (LOCF) Secondary endpoints Waist circumference Improved * Fasting triglycerides Improved * Fasting HDL cholesterol Improved * hs-CRP Improved * Cardiovascular measures Systolic blood pressure Decreased Diastolic blood pressure Decreased Pulse Inc
Slide 12: NB-302: Treatment-Emergent Adverse Events
NB-302: Treatment-Emergent Adverse Events Treatment Group Placebo NB32 Number of Subjects 200 584 Treatment Emergent AE 88.0% 93.7% * Nausea 10.5% 34.1% * Headache 17.5% 23.8% Constipation 14.0% 24.1% * Dizziness 4.5% 14.6% * Vomiting 6.5% 11.0% Insomnia 6.0% 8.7% Diarrhea 7.5% 7.4% Upper respirator
Slide 13: NB-302: Treatment-Emergent Psychiatric Adverse Events
NB-302: Treatment-Emergent Psychiatric Adverse Events Treatment Group Placebo NB32 Number of Subjects 200 584 Treatment Emergent AE 22.5% 25.0% Insomnia 6.0% 8.7% Anxiety 3.5% 5.1% Sleep disorder 3.0% 2.4% Depressed mood 4.0% 1.9% Abnormal dreams 2.0% 1.4% Depression 2.5% * 0.5% Middle insomnia 1.0%
Slide 14: NB-302: Adverse Events Resulting in Study Drug Discontinuation
NB-302: Adverse Events Resulting in Study Drug Discontinuation Treatment Group Placebo NB32 Number of Subjects 200 584 Discontinuation due to AE 13.0% 25.9% * Nausea 0 4.6% * Skin rash (hives) 0.5% 1.7% Anxiety 1.5% 1.2% Disturbance in attention 0 1.0% Headache 0.5% 0.9% Blood pressure increased 0 0
Orexigen Therapeutics — Technical Presentation (January 2009) on 6ix